StockData
Pfizer Inc logo

Pfizer Inc

PFENYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 28, 2026Last filing: 10-Q on Aug 4, 2026Score 11/3056% above fair value
$30.52+0.57 (+1.90%)

Close on Oct 30, 2026Market cap $173.95BP/E 40.2Yield 5.64%

Pfizer Oncology Portfolio Total [legacy] — U.S. by Year

Oncology Portfolio Total [legacy] — U.S. ($M) ($M)

Pfizer Oncology Portfolio Total [legacy] — U.S.: $12,512M in FY2025, up 8.2% from a year earlier. That is the highest of the 10 years on record here.

Latest, FY2025
12,512
Period ended Dec 31, 2025
Change on a year earlier
+8.2%
11,567 in FY2024
History
10 years
Since FY2016
Sources
9
Documents cited below

Where the FY2025 figure comes from

“|| Oncology | $ | 16,834 | $ | 15,612 | 8% | 8% | $ | 12,512 | $ | 11,567 | 8% | $ | 4,321 | $ | 4,045 | 7% | 6%”

Source: Form 8-K (Earnings / Guidance Release) (pfe-12312025xex99.htm, filed 2026-02-03) ↗

Reported in Form 8-K Revenue Tables.

Annual history

Hover a value to see the sentence it was read from; calculated values show their formula

Cite this data

StockData. (2026). Pfizer Oncology Portfolio Total [legacy] — U.S. ($M), annual FY2016–FY2025 [Data set]. Compiled from Pfizer SEC filings and investor materials. https://stockdatahq.com/stocks/pfe/kpis/port-leg-onc-us

See every metric in the Pfizer KPI table. Data updated Nov 2, 2026.